Recently, high-throughput ER chromatin immunoprecipitation sequencing (ChIP-seq) successfully identified a large number of ER-binding sites in breast cancer cells [30], [32], [33], which has transformed our understanding of how ER acts to alter cellular function. This evidence concerns the gene ESR1 and breast carcinoma.